Wall Street analysts forecast that Inovio Pharmaceuticals Inc (NASDAQ:INO) will post earnings of ($0.23) per share for the current quarter, according to Zacks. Three analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.24). Inovio Pharmaceuticals posted earnings per share of ($0.34) in the same quarter last year, which would indicate a positive year over year growth rate of 32.4%. The business is expected to report its next quarterly earnings report on Tuesday, March 10th.

On average, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.08) per share for the current financial year, with EPS estimates ranging from ($1.09) to ($1.05). For the next financial year, analysts expect that the company will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.92) to ($0.68). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. Inovio Pharmaceuticals had a negative return on equity of 179.91% and a negative net margin of 1,809.64%. The business had revenue of $0.87 million for the quarter, compared to analyst estimates of $2.72 million. During the same period in the previous year, the company posted ($0.27) earnings per share.

INO has been the topic of several recent analyst reports. Citigroup reaffirmed a “buy” rating and issued a $4.00 price target (down from $7.00) on shares of Inovio Pharmaceuticals in a research report on Monday, September 16th. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Inovio Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Maxim Group reissued a “buy” rating on shares of Inovio Pharmaceuticals in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $6.69.

Shares of NASDAQ:INO opened at $2.51 on Friday. The business has a 50 day moving average price of $2.38 and a 200 day moving average price of $2.53. The company has a debt-to-equity ratio of 2.52, a quick ratio of 5.06 and a current ratio of 5.06. Inovio Pharmaceuticals has a twelve month low of $1.91 and a twelve month high of $5.47.

Several large investors have recently bought and sold shares of the company. Wedbush Securities Inc. bought a new position in Inovio Pharmaceuticals in the third quarter worth $34,000. Stoneridge Investment Partners LLC bought a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at $50,000. Creative Planning bought a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at $50,000. LPL Financial LLC acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $61,000. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Inovio Pharmaceuticals by 140.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 32,802 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 19,144 shares in the last quarter. Institutional investors own 46.38% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Article: What is a good rate of return for a mutual fund?

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.